A Hidden Alzheimer's Tipping Point May Decide Who Gets Dementia
Researchers have identified a critical biological shift in brain immune cells called microglia that may determine whether Alzheimer's pathology leads to dementia.
An international research team, including scientists from VIB, KU Leuven, the UK-DRI, and Muna Therapeutics, has uncovered a major biological shift that could help explain why some people with Alzheimer's brain changes develop dementia while others remain cognitively healthy. The study, published in Nature Medicine, relied on donated brain tissue from older adults with and without cognitive decline, as well as from cognitively healthy centenarians.
Using advanced techniques such as spatial transcriptomics and single-cell sequencing, the researchers identified six distinct tissue domains representing different stages of Alzheimer's progression. They found that microglia – the brain's resident immune cells – undergo a dramatic change in behavior during the disease. Initially, microglia enter an inflammatory state associated with amyloid-beta plaques. Later, they transition to an antigen-presenting state that coincides with the appearance of tau pathology. This shift appears to be a biological tipping point that determines whether the disease progresses to neurodegeneration and dementia.
The study also revealed two distinct pathways to resilience. Octogenarians who had amyloid plaques but no dementia displayed the early microglial response but failed to transition to the later immune state. In contrast, centenarians activated the later microglial program, but this response occurred largely without being linked to tau accumulation. This suggests that resilience involves not just the absence of pathology but also how the brain controls its immune response.
These findings open new avenues for Alzheimer's treatment. Rather than focusing solely on plaque removal, future therapies might aim to preserve beneficial early microglial activity or modulate the transition between microglial states. Molecules such as TREM2 could become valuable therapeutic targets. Timing may also be critical: treatments could be most effective before the brain reaches the point where inflammatory activity becomes linked to tau pathology and cognitive decline.
